Paclitaxel - Generic Drug Details

What are the generic sources for paclitaxel and what is the scope of freedom to operate?

Paclitaxel is the generic ingredient in three branded drugs marketed by Accord Hlthcare, Actavis Totowa, Alembic, Dash Pharms, Fresenius Kabi Usa, Gland, Hikma, Hospira, MSN, Pharmobedient, Pliva Lachema, Sandoz, Teva Pharms, Teva Pharms Usa, Hq Spclt Pharma, Bristol-myers, Am Regent, Cipla, Hengrui Pharma, Mylan, Shuangcheng, and Teva Pharms Inc, and is included in twenty-four NDAs. There are eight patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Paclitaxel has two hundred and forty-four patent family members in thirty-two countries.

There are sixty-nine drug master file entries for paclitaxel. Eighteen suppliers are listed for this compound.

Summary for paclitaxel

International Patents:	244
US Patents:	8
Tradenames:	3
Applicants:	22
NDAs:	24
Drug Master File Entries:	69
Finished Product Suppliers / Packagers:	18
Raw Ingredient (Bulk) Api Vendors:	95
Clinical Trials:	4,319
Drug Prices:	Drug price trends for paclitaxel
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for paclitaxel
What excipients (inactive ingredients) are in paclitaxel?	paclitaxel excipients list
DailyMed Link:	paclitaxel at DailyMed

See drug prices for paclitaxel

Recent Clinical Trials for paclitaxel

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Northwell Health	PHASE1
National Cancer Institute (NCI)	PHASE3
American Cancer Society, Inc.	PHASE2

See all paclitaxel clinical trials

Pharmacology for paclitaxel

Drug Class	Microtubule Inhibitor
Physiological Effect	Microtubule Inhibition

Medical Subject Heading (MeSH) Categories for paclitaxel

Antineoplastic Agents, Phytogenic

Tubulin Modulators

Anatomical Therapeutic Chemical (ATC) Classes for paclitaxel

L01CD	Taxanes
L01C	PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS
L01	ANTINEOPLASTIC AGENTS
L	Antineoplastic and immunomodulating agents

Paragraph IV (Patent) Challenges for PACLITAXEL

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ABRAXANE	For Injection Suspension	paclitaxel	100 mg/vial	021660	1	2015-12-11

US Patents and Regulatory Information for paclitaxel

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Teva Pharms	PACLITAXEL	paclitaxel	INJECTABLE;INJECTION	075184-001	Jan 25, 2002	AP	RX	No	No
Bristol-myers	ABRAXANE	paclitaxel	POWDER;INTRAVENOUS	021660-001	Jan 7, 2005	AB	RX	Yes	Yes					Y
Shuangcheng	PACLITAXEL	paclitaxel	POWDER;INTRAVENOUS	216355-001	May 15, 2025	AB	RX	No	No

Expired US Patents for paclitaxel

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Hq Spclt Pharma	TAXOL	paclitaxel	INJECTABLE;INJECTION	020262-001	Dec 29, 1992
Bristol-myers	ABRAXANE	paclitaxel	POWDER;INTRAVENOUS	021660-001	Jan 7, 2005
Hq Spclt Pharma	TAXOL	paclitaxel	INJECTABLE;INJECTION	020262-001	Dec 29, 1992

EU/EMA Drug Approvals for paclitaxel

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Bristol-Myers Squibb Pharma EEIG	Abraxane	paclitaxel	EMEA/H/C/000778Abraxane monotherapy is indicated for the treatment of metastatic breast cancer in adult patients who have failed first-line treatment for metastatic disease and for whom standard, anthracycline containing therapy is not indicated.Abraxane in combination with gemcitabine is indicated for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas.Abraxane in combination with carboplatin is indicated for the first-line treatment of non-small cell lung cancer in adult patients who are not candidates for potentially curative surgery and/or radiation therapy.	Authorised	no	no	no	2008-01-11
ratiopharm GmbH	Pazenir	paclitaxel	EMEA/H/C/004441Pazenir monotherapy is indicated for the treatment of metastatic breast cancer in adult patients who have failed first-line treatment for metastatic disease and for whom standard, anthracycline containing therapy is not indicated.Pazenir in combination with carboplatin is indicated for the first-line treatment of non-small cell lung cancer in adult patients who are not candidates for potentially curative surgery and/or radiation therapy.	Authorised	yes	no	no	2019-05-06
Inceptua AB	Apealea	paclitaxel	EMEA/H/C/004154Apealea in combination with carboplatin is indicated for the treatment of adult patients with first relapse of platinum‑sensitive epithelial ovarian cancer, primary peritoneal cancer and fallopian tube cancer.	Authorised	no	no	no	2018-11-20

International Patents for paclitaxel

Country	Patent Number	Title	Estimated Expiration
Japan	2020011999	組成物及び薬物送達方法 (COMPOSITION AND METHOD OF DELIVERY OF PHARMACOLOGICAL AGENT)
South Korea	101857142
Spain	2678448

Supplementary Protection Certificates for paclitaxel

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0961612	132009901771196	Italy		PRODUCT NAME: PACLITAXEL(ABRAXANE); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/07/428/001, 20080114
0961612	CA 2009 00036	Denmark		PRODUCT NAME: PACLITAXELALBUMIN
0961612	300417	Netherlands		PRODUCT NAME: PACLITAXEL ALBUMINE; REGISTRATION NO/DATE: EU/1/07/428/001 20080114

Market Dynamics and Financial Trajectory for Paclitaxel

Last updated: January 15, 2026

Executive Summary

Paclitaxel, a cornerstone chemotherapeutic agent initially derived from the Pacific yew tree, remains a pivotal drug in cancer treatment, notably ovarian, breast, and non-small cell lung cancers. The drug’s market is shaped by factors including patent landscapes, generics emergence, regulatory protocols, regional demand variances, and evolving treatment paradigms. While facing competitive pressure from alternative therapies and biosimilars, paclitaxel’s market retains substantial revenue potential, estimated to reach USD 750 million globally by 2025. This analysis provides an in-depth review of the underlying market drivers, competitive landscape, revenue projections, and strategic outlooks, essential for stakeholders assessing investment and development opportunities within oncology pharmaceutics.

---

What Are the Key Market Drivers Influencing Paclitaxel?

Factor	Impact & Trends
Utilization in Oncology Protocols	Paclitaxel remains a first-line agent for ovarian, breast, and lung cancers, with over 70 countries integrating it into clinical guidelines (e.g., NCCN, ESMO).
Patent Expiry & Generics	Patents expired in key markets around 2014–2019, leading to widespread generic adoption; this has significantly reduced treatment costs and expanded access.
Biosimilar Entry	The development of paclitaxel biosimilars has intensified competition, lowering prices and constraining margins for originators (e.g., Bristol-Myers Squibb, Pfizer).
Regulatory and Reimbursement Policies	Stringent approval processes and national reimbursement schemes influence market penetration; regions like North America and Europe exhibit high adoption rates.
Emergence of Targeted & Immunotherapies	Increasing adoption of targeted therapies (e.g., PARP inhibitors, PD-1 inhibitors) could shift demand dynamics, either substituting paclitaxel or supplementing it.
Global Oncology Burden	Cancer incidence rates drive treatment demand; particularly rapid growth in Asian markets contributes to expanded opportunities.

---

How Is the Supply Chain and Manufacturing Landscape Structured?

Key Players	Market Share & Strategies
Major Manufacturers	Pfizer, Bristol-Myers Squibb, Teva, Hospira, and local producers in China and India dominate manufacturing, with a combined market share exceeding 70%.
Manufacturing Challenges	Complex extraction processes from natural sources historically limited production; now largely replaced by semi-synthetic manufacturing based on precursors like 10-deacetylbaccatin III.
Quality & Regulatory Compliance	Strict cGMP standards are enforced globally; recent disruptions relate to quality control in some biosimilar supplies, impacting trust and market stability.

---

What Are the Revenue Projections and Financial Trends?

Market Size & Growth (USD million)	Projection & Growth Rate	Notes
2018	620	Post-patent expiry, decline slowed after initial dip; growth from emerging markets started.
2023 (Estimated)	670	Stabilized with generics and biosimilar penetration; increased use in Asia-Pacific.
2025 (Forecast)	750	CAGR of approximately 4% from 2023–2025, driven by rising cancer incidence in developing regions and expanding indications.

Regional Market Share Breakdown (2023)

Region	Market Share (%)	Comments
North America	35	Mature market with high adoption, driven by reimbursement policies.
Europe	25	Similar to North America, with strong hospital procurement.
Asia-Pacific	25	Rapid growth due to increased cancer burden, cost sensitivity, and biosimilar penetration.
ROW (Rest of World)	15	Increasing uptake in Latin America, Middle East, and Africa.

---

What Are the Competitive and Regulatory Challenges?

Challenge	Implication
Patent Expiry & Biosimilar Competition	Price erosion necessitates strategic differentiation for originators; biosimilar entrants often price 30-50% lower.
Regulatory Hurdles	Approvals for biosimilars and new formulations require robust clinical data, extending timelines and increasing costs.
Pricing Pressures & Reimbursement Policies	Governments and payers emphasize cost-effectiveness, pressuring margins—especially in Europe and Asia.
Supply Chain Disruptions	Natural resource sourcing and manufacturing quality issues pose risks, impacting availability.

---

How Are Emerging Therapies Influencing the Market?

Emerging Therapies	Potential Impact	Status & Outlook
Targeted Agents & Immunotherapies	Complement or replace paclitaxel in combo regimens; may reduce long-term market share.	Approved drugs like pembrolizumab (Keytruda) are used in combination; ongoing trials explore synergy.
Nanoparticle & Liposomal Formulations	Enhanced delivery and reduced toxicity; may extend patent life or create new market segments.	Liposomal paclitaxel (e.g., Abraxane) is already marketed in specific indications.

---

How Will Regional Demand and Policy Trends Shape Future Market Trajectory?

Region	Growth Drivers	Challenges	Policy Trends
North America	Aging populations, high reimbursement rates	Cost containment, biosimilar competition	Favor generic/biosimilar use, incentive of value-based pricing
Europe	Established oncology protocols	Reimbursement constraints	Emphasis on cost-effectiveness, approval pace varies by country
Asia-Pacific	Rising cancer incidence, expanding healthcare infrastructure	Regulatory diversity, price sensitivity	Government-led procurement, supportive policies for generics/biosimilars
Latin America & Africa	Increasing healthcare access	Limited infrastructure, affordability	Growing adoption due to cost advantages of generics

---

Comparison: Paclitaxel vs. Alternative Chemotherapies

Parameter	Paclitaxel	Docetaxel	Albumin-bound Paclitaxel (Abraxane)	Emerging Alternatives
Source	Natural (from Pacific yew)	Synthetic	Albumin-bound formulation	Biosimilars/Biotreatments
Indications	Ovarian, breast, lung	Prostate, gastric	Breast, pancreatic	Targeted/immunotherapies
Pricing (USD)	~$50-200 per dose (generics)	Similar or slightly higher	~$300-400 per dose	Varies widely, often higher
Market Share (2023)	~25-30% of chemotherapy market	Similar	Growing segment	Increasing in specific indications

---

Strategic Outlook and Investment Considerations

Opportunities	Risks & Challenges	Strategic Recommendations
Expanding into emerging markets	Regulatory variability	Collaborate with local manufacturers; navigate regional policies.
Developing new formulations	R&D costs and uncertain regulatory success	Invest in liposomal, nanoparticle, or combination formulations to differentiate.
Leveraging biosimilar growth	Price erosion and market saturation	Focus on value-added services, quality assurance, and efficient supply chain management.
Monitoring evolving treatment algorithms	Rapid innovation may displace traditional chemotherapies	Stay ahead with clinical trial engagement and adaptive marketing strategies.

---

Key Takeaways

• Market stability for paclitaxel hinges on its entrenched role in chemotherapy protocols, despite significant patent expiries and biosimilar proliferation.
• Pricing and reimbursement pressures are intensifying globally, especially in Europe and Asia, demanding strategic adaptation from manufacturers.
• Emerging therapies such as immunotherapy and targeted agents pose competitive threats but also opportunities for combination treatments.
• Regional dynamics significantly influence market growth, with Asia-Pacific expected to be a primary growth driver, driven by rising cancer incidence and healthcare infrastructure.
• Future strategies should focus on formulation innovation, regional market expansion, and navigating regulatory landscapes to sustain profitability.

---

Frequently Asked Questions (FAQs)

1. How has the patent expiration affected the global market for paclitaxel?

Patent expiration, primarily occurring between 2014 and 2019, led to the entry of numerous generics, drastically reducing prices—by up to 50–70% in some regions—and increasing accessibility. This shift shifted revenue from originator companies to a broader manufacturing base, with average sales declining in mature markets but expanding due to increased volume and regional demand.

2. What are the primary regions driving future growth in paclitaxel sales?

The Asia-Pacific region is projected to be the fastest-growing market owing to higher cancer incidences, government support for biosimilars, and expanding healthcare infrastructure. North America and Europe will maintain significant revenues, although growth rates are expected to slow due to market maturity and pricing pressures.

3. How do biosimilars impact the market competitiveness of paclitaxel?

Biosimilars, offering comparable efficacy at lower prices, accelerate market penetration but also compress profit margins for original developers. Regulatory pathways for biosimilar approval ease market entry, particularly in regions like the EU, China, and India, further heightening competition.

4. Are there new formulations of paclitaxel that could extend its market life?

Yes. Liposomal formulations like Abraxane improve solubility, reduce toxicity, and enable higher dosing. Liposomal and nanoparticle-based formulations are in development, aiming to enhance efficacy and patient compliance, potentially creating new market segments.

5. How might emerging immunotherapies influence the demand for paclitaxel?

Immunotherapies and targeted agents are increasingly integrated into standard treatment regimens, sometimes replacing traditional chemotherapies like paclitaxel, especially in late-stage treatments. However, combination therapies may also sustain or even increase paclitaxel’s usage in certain contexts, particularly where cost-effective options are preferred.

---

References

1. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. 2022.
2. European Society for Medical Oncology (ESMO). Clinical Practice Guidelines. 2022.
3. MarketWatch. “Global Paclitaxel Market Size and Forecast (2018-2025).” 2023.
4. U.S. FDA. “Biosimilar Product Development and Approvals.” 2022.
5. IMS Health (IQVIA). “Oncology Market Trends,” 2022.
6. WHO. “Cancer Fact Sheet,” 2022.

Note: Data points, market figures, and projections are based on publicly available reports, company disclosures, and market analyses as of early 2023.

---

In conclusion, paclitaxel’s market remains vital but increasingly complex. Competition from generics and biosimilars, regulatory evolutions, and the rise of targeted therapies form a dynamic landscape requiring strategic agility. Stakeholders should leverage regional opportunities, innovate formulations, and monitor therapeutic trends to optimize long-term profitability.